Cargando…
Protection against Omicron BA.1/BA.2 severe disease 0–7 months after BNT162b2 booster
Following evidence of waning immunity against both infection and severe disease after 2 doses of the BNT162b2 vaccine, Israel began administering a 3rd BNT162b2 dose (booster) in July 2021. Recent studies showed that the 3rd dose provides a much lower protection against infection with the Omicron va...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035472/ https://www.ncbi.nlm.nih.gov/pubmed/36959496 http://dx.doi.org/10.1038/s42003-023-04669-6 |
_version_ | 1784911420360491008 |
---|---|
author | Amir, Ofra Goldberg, Yair Mandel, Micha Bar-On, Yinon M. Bodenheimer, Omri Freedman, Laurence Alroy-Preis, Sharon Ash, Nachman Huppert, Amit Milo, Ron |
author_facet | Amir, Ofra Goldberg, Yair Mandel, Micha Bar-On, Yinon M. Bodenheimer, Omri Freedman, Laurence Alroy-Preis, Sharon Ash, Nachman Huppert, Amit Milo, Ron |
author_sort | Amir, Ofra |
collection | PubMed |
description | Following evidence of waning immunity against both infection and severe disease after 2 doses of the BNT162b2 vaccine, Israel began administering a 3rd BNT162b2 dose (booster) in July 2021. Recent studies showed that the 3rd dose provides a much lower protection against infection with the Omicron variant compared to the Delta variant and that this protection wanes quickly. However, there is little evidence regarding the protection of the 3rd dose against Omicron (BA.1/BA.2) severe disease. In this study, we estimate the preservation of immunity from severe disease up to 7 months after receiving the booster dose. We calculate rates of severe SARS-CoV-2 disease between groups of individuals aged 60 and above, comparing those who received two doses at least 4 months previously to those who received the 3rd dose (stratified by the time from vaccination), and to those who received a 4th dose. The analysis shows that protection conferred by the 3rd dose against Omicron severe disease did not wane over a 7-month period. Moreover, a 4th dose further improved protection, with a severe disease rate approximately 3-fold lower than in the 3-dose cohorts. |
format | Online Article Text |
id | pubmed-10035472 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-100354722023-03-23 Protection against Omicron BA.1/BA.2 severe disease 0–7 months after BNT162b2 booster Amir, Ofra Goldberg, Yair Mandel, Micha Bar-On, Yinon M. Bodenheimer, Omri Freedman, Laurence Alroy-Preis, Sharon Ash, Nachman Huppert, Amit Milo, Ron Commun Biol Article Following evidence of waning immunity against both infection and severe disease after 2 doses of the BNT162b2 vaccine, Israel began administering a 3rd BNT162b2 dose (booster) in July 2021. Recent studies showed that the 3rd dose provides a much lower protection against infection with the Omicron variant compared to the Delta variant and that this protection wanes quickly. However, there is little evidence regarding the protection of the 3rd dose against Omicron (BA.1/BA.2) severe disease. In this study, we estimate the preservation of immunity from severe disease up to 7 months after receiving the booster dose. We calculate rates of severe SARS-CoV-2 disease between groups of individuals aged 60 and above, comparing those who received two doses at least 4 months previously to those who received the 3rd dose (stratified by the time from vaccination), and to those who received a 4th dose. The analysis shows that protection conferred by the 3rd dose against Omicron severe disease did not wane over a 7-month period. Moreover, a 4th dose further improved protection, with a severe disease rate approximately 3-fold lower than in the 3-dose cohorts. Nature Publishing Group UK 2023-03-23 /pmc/articles/PMC10035472/ /pubmed/36959496 http://dx.doi.org/10.1038/s42003-023-04669-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Amir, Ofra Goldberg, Yair Mandel, Micha Bar-On, Yinon M. Bodenheimer, Omri Freedman, Laurence Alroy-Preis, Sharon Ash, Nachman Huppert, Amit Milo, Ron Protection against Omicron BA.1/BA.2 severe disease 0–7 months after BNT162b2 booster |
title | Protection against Omicron BA.1/BA.2 severe disease 0–7 months after BNT162b2 booster |
title_full | Protection against Omicron BA.1/BA.2 severe disease 0–7 months after BNT162b2 booster |
title_fullStr | Protection against Omicron BA.1/BA.2 severe disease 0–7 months after BNT162b2 booster |
title_full_unstemmed | Protection against Omicron BA.1/BA.2 severe disease 0–7 months after BNT162b2 booster |
title_short | Protection against Omicron BA.1/BA.2 severe disease 0–7 months after BNT162b2 booster |
title_sort | protection against omicron ba.1/ba.2 severe disease 0–7 months after bnt162b2 booster |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035472/ https://www.ncbi.nlm.nih.gov/pubmed/36959496 http://dx.doi.org/10.1038/s42003-023-04669-6 |
work_keys_str_mv | AT amirofra protectionagainstomicronba1ba2severedisease07monthsafterbnt162b2booster AT goldbergyair protectionagainstomicronba1ba2severedisease07monthsafterbnt162b2booster AT mandelmicha protectionagainstomicronba1ba2severedisease07monthsafterbnt162b2booster AT baronyinonm protectionagainstomicronba1ba2severedisease07monthsafterbnt162b2booster AT bodenheimeromri protectionagainstomicronba1ba2severedisease07monthsafterbnt162b2booster AT freedmanlaurence protectionagainstomicronba1ba2severedisease07monthsafterbnt162b2booster AT alroypreissharon protectionagainstomicronba1ba2severedisease07monthsafterbnt162b2booster AT ashnachman protectionagainstomicronba1ba2severedisease07monthsafterbnt162b2booster AT huppertamit protectionagainstomicronba1ba2severedisease07monthsafterbnt162b2booster AT miloron protectionagainstomicronba1ba2severedisease07monthsafterbnt162b2booster |